Physician profile
Mark L Harrison
NPI 1417954124
$3,840.00
in general payments reported to CMS, 2019-2025
59 companies · $518 in 2025
The $518 reported for 2025 was more than what 75% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $477 · 2021: $813 · 2022: $539 · 2023: $548 · 2024: $588 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $407.09 | 2019-2025 | Tecvayli, Darzalex, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $219.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $190.58 | 2020-2024 | Krazati |
| Genentech USA, INC. | $179.79 | 2024-2025 | Tecentriq Hybreza, Tecentriq, Itovebi |
| Taiho Oncology, INC. | $155.74 | 2019-2024 | |
| Amgen INC. | $150.17 | 2019-2023 | Kyprolis |
| Eisai INC. | $147.46 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $135.80 | 2021-2024 | Keytruda, Welireg |
| Sobi, INC | $123.33 | 2022-2024 | |
| Incyte Corporation | $119.28 | 2020-2022 | |
| Sirtex Medical INC | $103.64 | 2022-2025 | Sir-Spheres Microspheres |
| Glaxosmithkline, LLC. | $102.05 | 2021-2024 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $93.02 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $90.53 | 2020-2023 | |
| Tersera Therapeutics LLC | $82.90 | 2023-2025 | Xermelo, Zoladex |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.